Vera Therapeutics (VERA) announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $300M of shares of its Class A common stock. All of the shares are being offered by Vera. J.P. Morgan, Goldman Sachs & Co., Evercore ISI and Cantor are acting as joint book-running managers for the proposed offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics files automatic mixed securities shelf
- Vera Therapeutics price target raised to $64 from $56 at Guggenheim
- Disney initiated, Cisco upgraded: Wall Street’s top analyst calls
- Vera Therapeutics initiated with an Outperform at Scotiabank
- Vera Therapeutics Expands Atacicept Autoimmune Kidney Studies